Phuturdex › Drugs › Relacorilant
Drugs in development · updated 30 October 2026
Relacorilant: clinical trials and development status
Other names and codes: Lifyorli (Copackaged), Lifyorli
As of 30 October 2026 Relacorilant is in 6 active clinical trials (recruiting or ongoing, phases I–III) for 18 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Relacorilant and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Fallopian tube neoplasm | III | 2 | NCT05257408 |
| Ovarian neoplasm | III | 2 | NCT05257408 |
| Peritoneal neoplasm | III | 2 | NCT05257408 |
| Adenocarcinoma | II | 1 | NCT07259317 |
| Adrenal cortex neoplasm | II | 1 | NCT03604198 |
| Adrenocortical carcinoma | II | 1 | NCT03604198 |
| Arterial hypertension | II | 1 | NCT03604198 |
| Cushing's syndrome | II | 1 | NCT03604198 |
| Endometrial neoplasm | II | 1 | NCT06906341 |
| Fallopian tube disease | II | 1 | NCT06906341 |
| Genital Neoplasms, Female | II | 1 | NCT06906341 |
| Neoplasm | II | 1 | NCT06906341 |
| Ovarian disease | II | 1 | NCT06906341 |
| Pancreatic ductal carcinoma | II | 1 | NCT07259317 |
| Pituitary ACTH Hypersecretion | II | 1 | NCT03604198 |
| Prostatic Neoplasms | II | 1 | NCT05726292 |
| Type 2 diabetes | II | 1 | NCT03604198 |
| Uterine cervix neoplasm | II | 1 | NCT07763496 |
Everything on Relacorilant
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.